CAMBRIDGE, Mass.–(BUSINESS WIRE)–KSQ
Therapeutics today announced the appointment of Douglas Pagán as
Chief Financial Officer. Mr. Pagán brings more than 25 years of
financial and operational experience in the biopharmaceutical industry.
He joins KSQ at a time when the company prepares to advance its first
drug programs into the clinic in 2020, addressing optimal therapeutic
targets based on its CRISPRomics™
technology. Additionally, KSQ announced the promotion of John Trzupek,
MBA, PhD, Head of Corporate Development and interim CFO, to the role of
Chief Business Officer.
“We are delighted to welcome Doug to the KSQ team,” said David Meeker,
MD, Chief Executive Officer of KSQ. “He has exceptional financial and
operational expertise, along with experiences across diverse
biopharmaceutical companies, that will be extremely valuable as KSQ
evolves into a clinical stage oncology company with multiple product
candidates. By growing and strengthening our leadership team, we are
further positioning KSQ to advance a broad pipeline of cancer medicines
that have been generated from our proprietary CRISPRomics engine.”
Dr. Meeker continued, “The promotion of John Trzupek to Chief Business
Officer is in recognition of his significant contributions in building
KSQ. John joined KSQ in December 2015 as one of the first five employees
of the company and has played an instrumental role translating the
CRISPRomics™ screening platform into an industry-leading product engine.”
Prior to joining KSQ, Mr. Pagán was Chief Financial Officer of Paratek
Pharmaceuticals, where he played a key role in transforming Paratek from
a development stage company to a commercial company, and he had
responsibility for finance, investor relations, strategic planning and
SEC reporting. Under his financial leadership, Paratek raised more than
$450 million in equity financing and maintained a strong balance sheet
to support the commercialization of the company’s first antibiotic
product.
Prior to Paratek, Mr. Pagán served as Vice President, Finance at
Acceleron Pharma Inc., where he was responsible for strategic and
financial planning, accounting, SEC reporting, treasury and financial
operations, and he played a significant role in the company’s Initial
Public Offering. Prior to working at Acceleron, he served in strategic
and financial management roles at Biogen Idec and Bristol-Myers Squibb.
Previously, Mr. Pagán worked in healthcare investment banking at J.P.
Morgan, as well as pharmaceutical operational roles at Johnson &
Johnson. Mr. Pagán received his BSE in Chemical Engineering from
Princeton University and his MBA from Columbia Business School.
“I am extremely pleased to be joining the KSQ team as the company
embarks on tremendous growth opportunities to advance medicines that
will have a meaningful impact for cancer patients,” said Mr.
Pagán. “KSQ’s progress to date is impressive in demonstrating the power
of CRISPRomics to rapidly generate a pipeline of cancer programs and to
create new medicines with the potential for improved success rates and
better outcomes for patients.”
About KSQ Therapeutics
KSQ
Therapeutics is using CRISPR technology within a powerful drug
discovery engine to enable high-confidence drug development. The company
is advancing a pipeline of
tumor- and immune-focused drug candidates for the treatment of cancer,
across multiple drug modalities including targeted therapies, adoptive
cell therapies and immuno-therapies. KSQ’s proprietary CRISPRomics™
drug discovery engine enables genome-scale, in vivo validated,
unbiased drug discovery across broad therapeutic areas. KSQ was founded
by thought leaders in the field of functional genomics and pioneers of
CRISPR screening technologies, and the company is located in Cambridge,
Massachusetts. For more information, please visit the company’s website
at www.ksqtx.com.
Contacts
Kathryn Morris
The Yates Network
Tel: 914-204-6412
kathryn@theyatesnetwork.com